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CoagulapathyEbolavirus and Marburgvirus are members of the ﬁlovirus family and induce a fatal hemorrhagic disease in
humans and nonhuman primateswith 90% case fatality. To develop a small nonhuman primatemodel for ﬁlovirus
disease, common marmosets (Callithrix jacchus) were intramuscularly inoculated with wild type Marburgvirus
Musoke or Ebolavirus Zaire. The infection resulted in a systemic fatal disease with clinical and morphological
features closely resembling human infection. Animals experienced weight loss, fever, high virus titers in tissue,
thrombocytopenia, neutrophilia, high liver transaminases and phosphatases and disseminated intravascular
coagulation. Evidence of a severe disseminated viral infection characterized principally bymultifocal to coalescing
hepatic necrosis was seen in EBOV animals. MARV-infected animals displayed only moderate ﬁbrin deposition in
the spleen. Lymphoid necrosis and lymphocytic depletion observed in spleen. These ﬁndings provide support for
the use of the common marmoset as a small nonhuman primate model for ﬁlovirus induced hemorrhagic fever.Immunology, Texas Biomedical
5-0549, USA. Fax: +1 210 670
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Ebolavirus (EBOZ) andMarburgvirus (MARV), members of the ﬁlo-
viridae family, are causative agents of hemorrhagic fever. Filovirus-
induced disease begins with ﬂu-like symptoms and progresses rapidly
to the ﬁnal stages of viral hemorrhagic fever infection, which are
characterized by fever, hemorrhage, and hypotensive shock (Groseth
et al., 2007; Zampieri et al., 2007). Infection is fatal in up to 90% as in
the case of Zaire Ebolavirus orMarburg Angola. The increased frequency
ofﬁlovirus outbreaks in central andwestern Africa and the potential use
of such agents as biological weapons underscore the need to under-
stand pathogenesis of these viruses and to develop effective interven-
tion strategies (Groseth et al., 2007; Peterson et al., 2004a,b).
Nonhuman primates (NHPs) are the preferred animal model for
humanﬁlovirus infection because infectionwith EBOZ andMARV isolated
from humans results in fatal hemorrhagic disease. Numerous species of
NHPs have been used, including baboons, African green monkey, rhesus
and cynomolgus macaques, to study ﬁlovirus pathogenesis because the
pathology of infected NHPs is similar to that seen in humans (Bente et
al., 2009; Geisbert et al., 2003b). The sporadic nature of disease outbreaks
and the ethical issues associated with conducting a human vaccine trialmake such a study difﬁcult to execute. Early-stage development of vac-
cines has historically occurred in mouse and guinea pig models of ﬁlo-
virus disease, but these models use adapted viruses obtained through
sequential passage in the rodent species because the wild-type virus
does not cause uniform lethality (Bray et al., 1999; Connolly et al.,
1999). The disease observed in rodents does not reproduce the extensive
disseminated intravascular coagulation seen in human ﬁlovirus disease.
Besides the requirement for an adapted virus, there are reports that
the rodent models are not necessarily predictive of efﬁcacy in NHPs
(Feldmann et al., 2003; Geisbert et al., 2002; Jahrling et al., 1996).
NHPs are relevant models to study infectious disease as their immune
system is similar to humans and they are good predictors of efﬁcacy in
vaccine development and other intervention strategies. Licensure of a
ﬁlovirus vaccine will require testing in a NHP species. The macaque
model is the most frequently used model in ﬁlovirus efﬁcacy studies
involving vaccines or therapies. Given the drawbacks of rodent models
of ﬁlovirus disease, there is a critical need for development of a small
animal model that develops disease consistent with human infec-
tion using wild-type virus.
The commonmarmoset (Callithrix jacchus) is an anthropoid primate
weighing between 320 and 450 g that is used extensively in biomedical
research and provides an attractive alternative to other NHPs
(Mansﬁeld, 2003). This small-bodied primate is especially valuable
in maximum containment research, where space is generally at a
premium. Additionally, reagents are available to characterize immu-
nological response to vaccines. Marmosets have been used to study a
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Lassa and Junin viruses, as well as Eastern Equine Encephalitis virus,
SARS-CoV, and hepatitis GB virus B, as well as other human syndromes
(Adams et al., 2008; Avila et al., 1985; Bright et al., 2004; Carrion et al.,
2007a; Greenough et al., 2005; Jacob et al., 2004; Lukashevich et al.,
2008; Mansﬁeld, 2003; Weatherford et al., 2009; Weissenbacher et
al., 1982). Marmoset models of Lassa hemorrhagic fever and Argentine
Hemorrhagic fever have been used to validate countermeasures against
the HFVs (Avila et al., 1987; Carrion et al., 2007b; Samoilovich et al.,
1984; Weissenbacher et al., 1986a,b).
Here we report that a single intramuscular injection of a common
marmoset with as little as 10 plaque forming units (PFU) of either
MARV or EBOV resulted in fatal hemorrhagic disease. The experimental
ﬁlovirus infections induced a systemic diseasewith histological features
similar to human infection, most notably hepatocellular necrosis and
extensive ﬁbrin deposition. The availability of a marmoset model for
ﬁlovirus induced disease is especially attractive since it provides a
small animal model for preclinical trials that is susceptible to viruses
isolated from humans without adaptation.Results
Clinical observations
All animals appeared normal until 3 days post-infection (DPI)
when weight loss and anorexia was observed. Animals infected with
1000 PFU EBOV were also febrile (N103 °F) at this time point. Animals
infected with 10 PFU of EBOV developed a fever 4 DPI. Similarly,
MARV infected animals developed a fever at days 5 and 6 for the
high dose and low dose, respectively. After the onset of fever, the be-
havior of animals changed: they became depressed, had reduced stool
production, and weight loss (5–7% from baseline). Just before death,
febrile response resolved and some animals became hypothermic.
Marmosets infected with Ebola virus succumbed to disease at 4 to
5 days DPI while MARV infected animals succumbed to disease at
six to eight DPI.
Complete blood counts and biochemical analyses (Table 1) were
performed on blood collected from marmosets. Beginning at 4 DPI,
blood contained elevated levels of serum alanine aminotransferases
(ALT), a marker of hepatocellular necrosis, which continued to increase
until the animal was euthanized. GGT (gamma-glutamyltransferase)
and ALP (alkaline phosphatase), measured to evaluate excretory liver
functions, were elevated N30-fold above baseline. Further evidence
of hepatic involvement was noted in MARV animals as a signiﬁcant
increase in total bilirubin (TBIL) observed just prior to death
(N3 mg/DL). Hematological data showed a reduction in numbers of
platelet in all animals over the course of infection with development of
leukocytosis (Fig. 1). All animals experienced an increase in neutrophils
and concomitant decrease in lymphocytes beginning at 2 DPI (Fig. 1).Table 1
Clinical chemistry from ﬁlovirus infected marmosets.
Animal number Inoculumn Dose (PFU) ALPa ALTa GGTa
28707 EBOV 10 21 362 94
28709 EBOV 1000 83 22 b5
28705 EBOV 1000 49 10 6
28716 EBOV 10 N2400 1341 578
29003 MARV 1000 1350 349 1440
29005 MARV 1000 355 463 2049
28554 MARV 1000 1069 406 1985
29784 MARV 1000 1101 606 N3000
29015 MARV 10 639 714 429
29018 MARV 10 319 381 1394
a Peak value after experimental infection noted in U/L.Viral load
The virulence of ﬁloviruses in humans is related to viremia, sug-
gesting that rate of virus replication is an important factor of patho-
genesis (Towner et al., 2004). At necropsy, tissue was collected from
marmosets for determination of viral load by qRT-PCR. Virus was
detected by 3 DPI, resulting in viremia greater than 5 to 7 log10 ge-
nome equivalents (GE) per milliliter on the day of necropsy. All tis-
sues contained amounts of viral RNA comparable with levels of
viremia (Table 2). At necropsy, differences in peak viral RNA level
in the tissues of animals infected with low (10 PFU) and high
(1000 PFU) doses of EBOV was observed. Viral load in blood from
MARV infected animals ranged from 2.88 log10 at day 2 to 8.15
log10 at day 7.
Gross pathology
Lesions seen in both EBOV marmosets and MARV marmosets were
similar. Hepatomegaly was seen in all animals and was often accompa-
nied by multifocal pigmentation and overall discoloration of the liver.
Splenomegaly was also a common ﬁnding at necropsy. Most animals
had lung abnormalities in most lobes, primarily hemorrhage and con-
gestion. Hemorrhage was frequently noted at the site of venipuncture.
Other ﬁndings included hemorrhage in bladder and adrenals as well
as light pigmentation present in lymph nodes.
Histology
Microscopic examination of tissue sections stainedwith hematoxylin
and eosin revealed a number of pathologic lesions (Tables 3 and 4).
Kidney
Renal lesions were observed in all EBOV-infected animals (Fig. 2A),
and consisted of ﬁbrin microthrombi lodged within capillary beds of the
glomerular tufts. Thrombi were apparent diffusely and often associated
with expansion of Bowman's space and accumulation of proteinaceous
ﬂuid. Polymorphonuclear cells were infrequently observed in glomerular
tufts and glomerular cells were necrotic. In conjunction, hypoxic nephro-
sis was evident in the proximal convoluted tubules of most animals and
was likely secondary to microthrombosis of the glomerular tufts.
MARV-infected animals were dissimilar: renal morphology was within
normal limits (Fig. 3A).
Lung
Lungs from all animals revealed ﬁbrin thrombi present within
large- to medium-sized pulmonary arteries (Fig. 2B). Thrombi often
contained increased numbers of neutrophils and pyknotic debris.
Perivascular lymphatics adjacent to these vessels were often dilated
and contained protein. Lungs were diffusely congested and multiple
foci of ﬁbrin microthrombi were evident in many small arterioles,
extending into capillary beds and associated with congestion and
hemorrhage. Occasionally extravasated erythrocytes were mixed
with evidence of proteinaceous exudates in alveolar spaces.
In contrast, pulmonary changes were minimal to mild in MARV-
infected marmosets. One animal (29015) receiving 10 PFU and one
receiving 1000 PFU developed mild edema surrounding small pulmo-
nary arteries. In addition, three animals had evidence of a mild focal
interstitial pneumonitis characterized by neutrophilic inﬁltration,
septal necrosis and variable alveolar edema. It is unlikely that the pul-
monary ﬁndings were of clinical signiﬁcance.
Liver
Hepatic lesions in EBOV-infected marmosets were observed in all
animals but differed dependent on the dose and day of death
(Fig. 2C). In animals inoculated with 1000 PFU of EBOV, hepatic lesions
were mild and consisted of multifocal inﬁltrates of polymorphonuclear
Fig. 1. Hematology data frommarmosets experimentally inoculatedwithﬁloviruses. Animals infectedwith both Ebolavirus (top left) andMarburgvirus (top right) developed neutrophilia
with a concomitant decrease in lymphocytes. Total white blood counts (bottom left) increased during the course of infection while thrombocytopenia (bottom right) developed. Because
of the limited samples size, data points are represented as geometrical means of data corresponding to timepoint regardless of virus dose.
Table 3
Histologic ﬁndings in marmosets inoculated with EBOV.
Animal number 28709 28705 28707 28716
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of sinusoidal cells. Viral inclusionswere not observed. In animals inocu-
lated with the 10 PFU and surviving to 5 dpi, hepatic disease was more
severe and characterized bymultifocal to coalescing hepatocellular coa-
gulative necrosis inﬁltrated by small to moderate numbers of neutro-
phils. Hepatocytes within and adjacent to these regions of necrosis
often contained large amphophilic intracytoplasmic inclusions
(Fig. 2D). Inclusions had an asymmetric perinuclear distribution.
These more severe changes were accompanied by intracellular biliary
stasis. The ﬁndings suggest initial targeting of resident sinusoidal cells
(Kupffer and monocytes) with subsequent extension to adjacent
hepatocytes.
MARV-infected animals all displayed multifocal to coalescing hepa-
tocellular necrosis. Necrotic foci varied from individual hepatocytes toTable 2
Viral load in ﬁlovirus infected marmoset tissue.
Tissue Log10 genome equivalents/100 mg tissuea
Ebola
(10 PFU)
Ebola
(103PFU)
Marburg
(10 PFU)
Marburg
(103PFU)
Adrenal 8.348 7.493 7.899 7.98
Bladder 7.387 6.051 6.827 7.498
Brain 5.761 5.179 6.965 6.968
Colon 6.6 5.093 6.835 7.089
Duodenum 7.609 5.758 5.702 7.481
Heart 6.322 5.364 7.856 7.573
Ileum 6.614 5.525 6.276 6.97
Kidney 7.916 6.532 7.448 7.604
Liver 7.715 6.364 8.178 8.277
Lung 5.966 6.749 8.003 7.898
Lymph nodes 8.152 7.245 7.171 7.25
Muscle 6.584 6.045 7.966 7.116
Pancreas 6.186 4.842 6.574 6.974
Spleen 6.983 7.587 8.051 8.561
Stomach 6.963 5.121 5.42 6.779
a Viral load is represented as geometric mean of two animals per group.small aggregates of cells up to 300 μm in diameter. Necrotic hepatocytes
had rounded and deeply eosinophilic homogeneous to granular appear-
ing cytoplasmwith pyknotic or karyorrhectic nuclei (Fig. 3B). Occasion-
ally, hepatocytes in the early phases of degeneration had well deﬁned
eosinophilic bodies present within the cytoplasm (eosinophilic degen-
eration) but the amphophilic inclusions were infrequently ob-
served (Fig. 3C). Dispersed within and adjacent to these regions
of necrosis were increased numbers of neutrophils found within sinu-
soids and mixed with the necrotic debris. In four animals there wasDose 103PFU 103PFU 10 PFU 10 PFU
Survival (days) 4 4 5 5
Liver
Necrosis + + ++ +++
Inclusion − − present present
Adrenal
Thrombi ++ − ++ −
Necrosis ++ − ++ +
Lung
Thrombi ++ + ++ +
Hemorrhage and congestion ++ + ++ +
Spleen
Lymphoid depletion + + ++ +++
Fibrin deposition ++ ++ ++ +++
Lymph node
Lymphoid hyperplasia − ++ − ++
Lymphoid depletion +++ + +++ +
Neutrophilic inﬁltrates ++ + + +
Hemorrhage ++ + +++ +
Urinary tract
Glomerular tufts ﬁbrin ++ +++ ++ ++
Hypoxic nephrosis ++ +++ ++ +
Hemorrhage bladder + ++ n/a −
– is absence of lesion; + is mildly; ++ moderately affected; severely affected +++.
Table 4
Histologic ﬁndings in MARV virus inoculated animals.
Animal number 29003 29005 28554 29784 29015 29018
Dose 103PFU 103PFU 103PFU 103PFU 10 PFU 10 PFU
Survival (days) 8 7 8 7 6 7
Liver
Hepatic necrosis ++ ++ ++ ++ ++ ++
Hepatocellular dissociation ++ − + + − +
Neutrophilic inﬁltrates + + + + + +
Hepatocellular fatty change ++ − + + +
Adrenal
Extramedullary hematopoiesis − − + ++ − +
Adrenalitis/necrosis + + + + ++ +
Lung
Pneumonitis − − + + + −
Perioarteriolar edema + − − − + −
Spleen
Necrosis ++++ +++ +++ ++++ + ++
Lymphocytic depletion +++ +++ +++ ++++ + ++
Fibrin deposition medullary cords ++ ++ ++ ++ + +
Lymph node
Necrosis ++ − n/a + − −
Lymphocytic depletion + − + − −
Thymus − n/a + n/a − n/a
Bone marrow, kidney, heart, skeletal muscle,
brain, gastrointestinal tissue
PMA WNL WNL WNL WNL WNL
− is absence of lesion; + is mildly affected ; ++ moderately affected; +++ severely affected WNL is within Normal Limits.
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of hepatocellular necrosis was similar regardless of inoculum.
Spleen
Spleens of all EBOV-infected animals were depleted of lymphocytes
and contained deposits of ﬁbrin (Fig. 2E). Extensive ﬁbrin deposits
were observed within the red pulp. These changes were accompanied
by necrosis of cells within the Cords of Billroth in severely affectedFig. 2. Pathology of EBOV viral infection in common marmosets. Inoculation of EBOV viru
(A) and lung (B). Multifocal focal hepatic necrosis (C) and characteristic intracytoplasmic v
(E) and peripheral lymph nodes (F). Fibrin deposition was widespread in medullary cordsanimals. Lymphocyte depletion was severe and appears to be focused
on periarteriolar sheaths (T cell regions) and to a lesser extent follicular
(B cell) regions. In most residual areas of white pulp, pyknotic and kar-
yorrhectic nuclear debris was evident and these regionswere inﬁltrated
by polymorphonuclear cells at multiple foci. In marmosets given 1000
PFU of virus, involvement of B cell regions was signiﬁcantly less. In con-
trast, all animals receiving 1000 PFU MARV inoculum had evidence of
marked lymphocyte depletion and lymphoid necrosis in the spleens produced disseminated microvascular thrombosis evident in glomerular capillaries
iral inclusions were evident (D, arrow). Lymphoid necrosis was observed in the spleen
of the spleen (E).
Fig. 3. Pathology of MARV virus infection in common marmosets. Microvascular glomerular thrombosis was not observed in animals inoculated with MARV virus and glomeruli
(A) appeared histologically normal. Multifocal hepatic necrosis (B) and characteristic intracytoplasmic hepatocellular viral inclusions were observed (C). Lymphoid necrosis within
periarteriolar sheaths of the spleen (D) and ﬁbrin deposition within splenic medullary cords (E) was evident. In contrast to EBOV infection peripheral lymph nodes appeared normal
(F).
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duced in size and contained pyknotic and karyorrhectic debris. The
changes were present to a lesser degree in the 10 PFU group, suggesting
that viral dose may have been responsible for the observed differences.
Fibrin deposition was observed in the medullary cords and correlated
with the degree of lymphoid necrosis and lymphocytic depletion.
Lymph node (axillary)
In two EBOV animals, mild to moderate lymphocytic hyperplasia
was observed in cortical parafollicular regions, accompanied by in-
creased numbers of tingible body macrophages. In these nodes, scat-
tered areas of hemorrhage and necrosis were occasionally apparent. In
contrast, in the two remaining animals, therewas evidence of extensive
lymphocytic necrosis that was focused in medullary and parafollicular
regions, while follicles were spared. These changes were accompanied
by hemorrhage, neutrophilic inﬁltration and extensive ﬁbrin deposition
(Fig. 2F).
Changes in lymph node morphology were apparent in only 2 of 6
MARV-infected animals, and consisted of mild to moderate lymphoid
necrosis and lymphocytic depletion. In the remaining animals, there
was an absence of secondary follicles with germinal centers but lym-
phocyte numbers appeared normal (Fig. 3F).
Adrenal gland
Fibrin microthrombi were observed in the adrenal glands of some
EBOV-infected animals and were most frequently observed in the
subcapsular region in the zona glomerulosa. Thrombiwere accompanied
by congestion and hemorrhage. Multifocal dissociation and necrosis
of cortical adrenocytes was evident in a subset of animals and was
occasionally accompanied by inﬁltration by a small number of poly-
morphonuclear cells. No viral inclusions were evident. Fibrin was not
observed in MARV animals. Within adrenal glands there were multiple
scattered areas of necrosis of individual and small aggregates ofadrenocytes accompanied by the presence of erythrocytes, lympho-
cytes and mononuclear cells.
Other organs
Lesions were observed inconsistently in other organs and were
often related to the effects of disseminated intravascular coagulation
and terminal hypoxia. These included evidence of myocardial hypoxic
necrosis, and microhemorrhages in the brain, heart, urinary bladder
and pancreatic islets. Two animals infected with 1000 PFU of MARV
had evidence of a mild focal ﬁbrosis, which dissected along muscle
fascicles and was associated with scant histiocytic and lymphocytic
inﬁltrates. Findings in other organs were unremarkable.
Discussion
We report for the ﬁrst time that the common marmoset is suscepti-
ble to experimental infection with viruses from the family Filoviridae.
The intramuscular inoculation of as little as 10 PFU of either EBOV or
MARV induced pathological features similar to those observed in
human disease. Most notably, animals experienced thrombocytopenia,
neutrophilia and disseminated intravascular coagulation. Furthermore,
the small nonhuman primate experiences a disease syndrome compa-
rable to what has been reported in other nonhuman primate models
currently used to study ﬁlovirus disease.
Cynomolgus macaques are frequently used in preclinical testing
of ﬁlovirus vaccine and therapeutic strategies and are considered
the “gold standard” animal model (Bente et al., 2009). Experimental
EBOV infection of macaques by intramuscular injection of 1000 PFU
of virus results in a rapid fatal disease. Beginning at 4 DPI, ma-
caques experienced anorexia coinciding with the onset of fever.
Shortly after these initial ﬁndings, petechial rash was seen with
varying degrees of recumbency, culminating in prostration and
death at 7 days post-challenge (Geisbert et al., 2003d). We ob-
served a similar, although shortened (death 4–5 DPI), course of
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shown that intramuscular inoculation of macaques with MARV re-
sults in an analogous course of disease; however, overall disease
progression was delayed with death occurring between days
8 and 13 (Bente et al., 2009; Geisbert et al., 2007; Jaax et al.,
1996). Consistent with the macaque model, experimental inocula-
tion of marmosets with MARV also results in delayed onset of dis-
ease, with death occurring 3 to 4 days later than that seen with
marmosets infected with EBOV. However, the course of Marburg
disease in marmosets was more rapid than that seen in macaques,
with death occurring at 6 to 8 DPI. Although not statistically signiﬁcant,
it is interesting to note that MARV infected marmosets had an average
time to death 1 day shorter than those receiving a high dose of virus.
Human ﬁlovirus infection is marked by neutrophilia, lymphopenia
and thrombocytopenia. These ﬁndings are observed in the macaque
model of ﬁlovirus disease and are used as surrogate markers of
disease progression for in vivo studies (Geisbert et al., 2003b; Simpson,
1969; Simpson et al., 1968). Marmosets infected with either of the
ﬁloviruses also display these hematological abnormalities. Beginning
at 2 DPI, overall platelet counts decreased while neutrophil numbers
increased, with a concomitant decrease in lymphocyte numbers (Fig. 1).
Autopsy ﬁndings from fatal human cases reveal hepatomegaly
with necrotic foci observed throughout liver. Likewise, experimentally
infected macaques developed numerous hepatic lesions (Geisbert et
al., 2003b,c,d, 2008; Jaax et al., 1996). The marmoset showed bio-
chemical signs of liver involvement early in infection: markers of
liver function (ALT, ALP, GGT) reached levels in excess of 30-fold
above baseline at necropsy. Consistent with high-levels of liver en-
zymes, gross examination of the liver revealed hepatomegaly with
pale foci throughout all lobes. Microscopic examination of sections
from the liver revealed necrosis with mild to moderate inﬂammation.
Hepatic changes did not appear to be virus dose-dependent, although
further animal or morphometric studies would be needed to conﬁrm
this. Evidence of mild to moderate hepatocellular fatty change was
present. Similar ﬁndings have been documented in the macaque
model of ﬁlovirus infection and most importantly, the ﬁndings
reported here are comparable to those reported in fatal human cases
(Geisbert et al., 2003b,c, 2008; Jaax et al., 1996).
One difference between the macaque model of ﬁlovirus infection
and marmosets is that marmosets do not develop a petechial rash.
In this respect, they appear to be more similar to the African green
monkey model of ﬁlovirus infection (Bente et al., 2009; Davis et al.,
1997). We speculate that the rapid disease progression preempts its
development. Nonetheless, clear signs of coagulation abnormalities
are pronounced, as animals experience thrombocytopenia, hemor-
rhage and bleeding at sites of venipuncture. Fatal human cases are
characterized by hemorrhage and bleeding at site of venipuncture
and other coagulation abnormalities. The coagulopathy observed in
humans at times exists in the absence of rash: only 50% of patients
infected with EBOV develop a maculopapular rash (Bwaka et al.,
1999). Further evidence that the marmoset mimics human disease
is that microscopic examination of tissue from EBOV-infected animals
reveals widespread ﬁbrin deposition that is a hallmark of coagulation
abnormalities (Geisbert et al., 2003c,d; Jaax et al., 1996). EBOV infec-
tion of the marmoset caused a severe disseminated viral infection
characterized principally by microthrombosis in multiple organs (dis-
seminated intravasculature coagulation). To a lesser degree, MARV-
infected animals displayed moderate ﬁbrin deposition in the spleen.
A similar observation has been reported for rhesus macaques infected
with Marburgvirus Angola where deposition of polymerized ﬁbrin
was less pronounced than in EBOV infected macaques (Geisbert et
al., 2007). These ﬁndings are similar to that seen in human infection
and the macaque (Geisbert et al., 2003a,b,c; Jaax et al., 1996). Signs
of coagulopathy characteristic of primate infections are observed var-
iably in rodent models (Bente et al., 2009; Bray et al., 1999; Connolly
et al., 1999).High levels of viremia in human ﬁlovirus infections are associated
with high mortality. A 2-log difference in titers is sufﬁcient to predict
clinical outcomes (Towner et al., 2004). Inoculation of macaques with
either EBOV or MARV results in high viral loads in both blood and tis-
sue (Geisbert et al., 2003d). In the current study, all marmosets had
high virus loads (N106) in blood and tissue regardless of dose or
agent. Consistent with human cases, virus was widely disseminated,
with the spleen and liver frequently having levels 1-log higher than
other tissue. In animals given 1000 PFU EBOV, viral load was 2-logs
less than those in animals receiving 10 PFU of virus. This difference
could be a result of a rapid onset of morbidity affecting viral load.
Virus load in animals infected with MARV was similar and likely the
result of relatively longer time to death compared to EBOV animals.
It is worthwhile noting that recently it has been shown that ﬁlovirus
replication results in a surplus of genomes with varying degrees of
packaging efﬁciency and infectious particles. In the in vitro studies,
the ratio of RNA to focus forming units was 100-fold more in EBOV
versus MARV (Weidmann et al., 2011). Taking this into account, the
difference in virus load between MARV and EBOV infected marmosets
may be correspondingly different.
Differences in histopathology were observed between animals in-
oculatedwithMARV and EBOV. EBOV infection resulted inwidespread
intravascular coagulation apparent in multiple organs including the
spleen, adrenal gland, kidney and lung (Fig. 2 and Table 3). There
was evidence of extensive lymphocytic necrosis focused in medullary
and parafollicular regions, while follicles were spared. These changes
were accompanied by hemorrhage, neutrophilic inﬁltration and
extensive ﬁbrin deposition (Fig. 2F). Findings suggest initial activation
within T lymphocyte areas followed by subsequent and rapid lympho-
cytic depletion, most likely through apoptotic mechanisms. Comparing
changes to changes observed in the spleen suggests alterations in the
lymph node lag behind those observed in the spleen. MARV animals
inoculatedwith 1000 PFU hadmoderate ﬁbrin deposition in the spleen,
widespread intravascular coagulation was not observed, suggesting a
signiﬁcant difference in pathogenesis between the two agents (Fig. 3
and Table 4).
The observation that hepatic lesions are less severe in animals re-
ceiving high dose of virus versus a lower dose is difﬁcult to explain
with a small sample size. The virus preparation used to infect the mon-
keyswas prepared at a lowmoi in order tominimize the effect of DI par-
ticles. It is known in ﬁlovirus infection, hepatic lesions early in infection
are less severe than those at terminal endpoints (Geisbert et al., 2003a,
b,c,d). Perhaps the relatively quick time to death in those animals
infected with high dose of virus preempted the development of severe
liver pathology.
Our study has shown that intramuscular inoculation of marmosets
with EBOV or MARV causes hemorrhagic fever reminiscent of human
infection. Since nonhuman primates are more predictive of ﬁlovirus
therapeutic efﬁcacy than rodents, the small-sized marmoset is a viable
alternative small animal model. The marmoset size is comparable to
that of a guinea pig, making it attractive for testing therapeutic reagents
that are only available in small quantities. In addition, the neotropical
monkey can serve to alleviate the shortage of macaques available
for research (Patterson & Carrion, 2005; Satkoski et al., 2008). That
the common marmoset is susceptible to wild-type, non-adapted virus
is especially attractive to those wishing to evaluate countermeasures
in a small animal model with viruses derived from fatal human cases.
Materials and methods
Biosafety
EBOZ and MARV are Risk Group 4, Category A biothreat agents. All
experiments with this virus were performedwithin a biosafety level 4
(BSL4) facility by personnel in a biosafety suit at the Texas Biomedical
Research Institute (San Antonio, TX). Both the Institutional Animal
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at Texas Biomed approved experimental protocols.
Virus strains
EBOV (Kikwit) andMARVMusokewere provided byDr. Peter Jahrling
(USAMRIID, Fort Detrick, Maryland). Stocks were used to infect tissue
culture ﬂasks containing Vero E6 cells at 90% conﬂuency. The ﬂasks
were infected at an MOI of 0.01 then incubated until cytopathic effect
greater than 80% was observed then harvested and stored in aliquots
in an ultralow temperature freezer. Infectivity of virus stocks was
determined by plaque titration (Moe et al., 1981).
Animals
Ten adult marmosets ranging in weight from 331 g to 425 g were
obtained from the Southwest National Primate Research Center in San
Antonio, Texas. One week before the start of the study, animals were
transferred to the BSL4 facility at Texas Biomed and housed individually
in a climate controlled caging. At day 0, animalswere injected intramus-
cularly (0.5 mL) with either EBOV (10 PFU, n=2; 1000 PFU, n=2) or
MARV (10 PFU, n=2; 1000 PFU, n=4) diluted in PBS. Animals
were sedated and blood was collected at days 0, 2, 5 and 7 for analysis.
Animals were euthanizedwhenmoribund using approvedmethods. All
procedures were approved by the Texas Biomed Institutional Animal
Care and Use Committee andwere performed in accordancewith appli-
cable federal guidelines.
Hematology and blood chemistry
Biochemical analysis of plasma samples was performed using
mammalian liver enzyme proﬁle rotor on Vet Scan analyzer (Abaxis,
Inc., Union City, CA). Complete blood counts were performed using
a Vet HMT machine (Abaxis, Inc., Union City, CA).
Tissue preparation and staining
Tissuewas collectedusing sterilized scalpels and forceps. Tominimize
contamination of tissue with blood, tissue samples were harvested after
blood collection. Aseptically collected tissues were ﬁxed in phosphate-
buffered 4% paraformaldehyde (pH 7.2) and embedded in parafﬁn for
histological examination. Parafﬁn-embedded tissues were cut in 5-μm
sections, deparafﬁnized and stained with hematoxylin and eosin.
Total RNA Isolation and qRT-PCR
Viral load in tissues were measured by quantitative RT-PCR (qRT-
PCR). Tissue was homogenized with Trizol Reagent (Invitrogen) using
the TissueLyser (Qiagen Inc., Valencia, CA) homogenization system and
RNA extracted per the manufacturer's recommendations. Real-time
qRT-PCR was performed using an ABI PRISM 7700 Sequence Detection
System (Applied Biosystems, Foster City, CA) and RNA Ultrasense one-
step real-time qRT-PCR system (Invitrogen). The EBOV qRT-PCR assays
were performed as previously described (Sun et al., 2009). MARV qRT-
PCRwas performed as described above using a primer/probe set directed
at a region within the MARV glycoprotein (MAGP-F: 5′GGCCTTCAGGG-
CAGGTGTA 3′, MAGP-R : 5′ CCTGTGCATGAGGGTTTTGA 3′, MMGP-
Probe: 5′ FAM-CCTTGCTGTTAGATCCTCCTACCAA-TAMRA 3′).
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